0 works0 citations0 h-index

Marc Bourlière

Inserm(FR)Aix-Marseille Université(FR)Hôpital Saint Joseph(FR)Economic & Social Sciences, Health Systems & Medical Informatics(FR)Institut de Recherche pour le Développement(FR)

Publications by Year

Research Areas

Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Liver Disease and Transplantation, HIV/AIDS drug development and treatment

Most-Cited Works

→ Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial(2019)1,186 cited
→ Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection(2009)1,023 cited
→ Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening(2016)1,001 cited
→ Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection(2015)845 cited
→ Advancing the global public health agenda for NAFLD: a consensus statement(2021)709 cited
→ Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study(2019)617 cited

→ Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection(2017)559 cited

→ Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).(2003)554 cited

→ Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications(2016)532 cited

→ Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin(2014)515 cited